New Test Gauges Danger of Rejection When Children Need Organ Transplants

November 21, 2014

(Managed Care Magazine) – Until now, no predictive tool existed for a risk-based customization of the immunosuppression therapy. That may now change. A group from the University of Pittsburgh, one of the pioneer transplant sites, has come up with an FDA-approved predictive test that has been shown to help with this decision making. The test, called Pleximmune, is available from a small corporation called Plexision, also located in Pittsburgh. Pleximmune is an aid in the evaluation of the risk of acute cellular rejection and must be used in conjunction with biopsy, standard clinical assessment, and other laboratory information.